Boai New Open Medical Technology Group Co., Ltd. 2025 Annual Independent Director Performance Report (Fang Yongjun)
To All Shareholders and Shareholder Representatives:
As an independent director of Boai New Open Medical Technology Group Co., Ltd. (hereinafter referred to as the "Company"), I have consistently adhered to the provisions of the "Company Law," "Securities Law," "Administrative Measures for Independent Directors of Listed Companies," "Shenzhen Stock Exchange Listed Company Self-Regulatory Management Guide No. 2 - Normative Operation of GEM Listed Companies," and the "Articles of Association" and other laws, regulations, and normative documents in 2025. I have upheld the principles of independence, objectivity, and prudence, actively attended board and special committee meetings, carefully reviewed various proposals and related materials, and proactively paid attention to the Company's operating conditions and development strategies. I have utilized my professional background and practical experience to prudently express independent opinions, effectively safeguarding the overall interests of the Company and the legitimate rights and interests of all shareholders, especially small shareholders. Herein is my performance report for 2025:
I. Basic Information of Independent Director
Fang Yongjun, male, born in 1972, Chinese national, with no permanent overseas residency, a member of the Communist Party of China, and a certified public accountant in China. He graduated with a bachelor's degree in Accounting from Henan University of Finance and Economics in 1993 and obtained a Ph.D. in Management (Financial Management) from Zhongnan University of Economics and Law in 2009. He previously served as the Director of the MPAcc Center, Vice Dean of the School of Accounting, and Deputy Director of the Graduate School at Henan University of Finance and Economics. He is currently a professor at the School of Accounting, Zhongnan University of Economics and Law.
I do not hold any positions in the Company other than that of an independent director, nor do I hold any positions in the Company's major shareholders. Apart from the independent director's allowance, I have not received any additional undisclosed benefits from the Company, its major shareholders, or related parties, which meets the independence requirements stipulated in Article 6 of the "Administrative Measures for Independent Directors of Listed Companies."
II. Performance in 2025
(I) Meeting Attendance
In 2025, the Company held a total of 6 board meetings and 2 shareholder meetings. I personally attended all board meetings and attended all shareholder meetings as required, without any entrusted attendance or absences. Before the meetings, I carefully reviewed the meeting materials, actively communicated with the Company's management and other directors on the matters to be deliberated, and actively participated in the discussions of various proposals during the meetings, expressing independent opinions based on professional judgment.
During the reporting period, the convening and holding of the Company's board meetings and shareholder meetings, as well as their resolutions, complied with laws and regulations and the "Articles of Association." The necessary approval procedures were followed for major decision-making matters, and no situations were found that harmed the legitimate rights and interests of the Company and all shareholders (especially small shareholders). Based on prudent judgment, I voted in favor of all proposals, with no dissenting, opposing, or abstaining votes. The specific situation is as follows:
| Meeting Type | Board Meetings |
|---|---|
| Number of meetings convened | 6 |
| Number of meetings to attend | 6 |
| Number of personally attended meetings | 6 |
| Number of entrusted attendance meetings | 0 |
| Number of absent meetings | 0 |
| Whether consecutive absences from board meetings | No |
| Number of shareholder meetings attended | 2 |
| Number of shareholder meetings to attend | 2 |